Vertex falls after CF data

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) fell $5.07 (10%) to $48.07 on Thursday after reporting interim Phase II data for a combination of two cystic fibrosis candidates. Although

Read the full 267 word article

How to gain access

Continue reading with a
two-week free trial.